Outlook Therapeutics(OTLK) - 2024 Q3 - Quarterly Results

Exhibit 99.1 Outlook Therapeutics Reports Financial Results for Third Quarter Fiscal Year 2024 and Provides Corporate Update · Received European Union (EU) and United Kingdom (UK) Marketing Authorization for LYTENAVA™ (bevacizumab gamma) for the treatment of wet AMD · NORSE EIGHT current enrollment pace supports topline readout target of Q4 CY2024 · Resubmission of the ONS-5010 Biologics License Application (BLA) on track for Q1 CY2025 · Quarterly update conference call and webcast today, Wednesday, August ...